Avantor® and BlueWhale Bio Partner to Accelerate CAR-T Manufacturing with Breakthrough Cell Activation and Expansion Technology
Avantor (NYSE: AVTR) announced a strategic partnership with BlueWhale Bio on Oct 15, 2025 to accelerate CAR-T manufacturing by scaling production of Synecta™ cell-derived nanoparticles (CDNPs).
The collaboration combines Avantor's bioprocessing and GMP manufacturing capabilities with BlueWhale Bio's Synecta CDNP platform, aiming to produce GMP-grade CDNP materials to shorten CAR-T expansion time and increase manufacturing capacity.
BlueWhale Bio data cited earlier cell division, higher cell yields, and fewer process interventions, and notes Synecta T1 CDNPs are used in a 3-day CAR-T clinical trial.
Avantor (NYSE: AVTR) ha annunciato una partnership strategica con BlueWhale Bio il 15 ottobre 2025 per accelerare la produzione di CAR-T mediante l'aumento della produzione di nanoparticelle derivate da cellule Synecta™ (CDNPs).
La collaborazione combina le capacità di bioprocessing e GMP di Avantor con la piattaforma CDNP Synecta di BlueWhale Bio, con l'obiettivo di produrre materiali CDNP conformi GMP per accorciare i tempi di espansione del CAR-T e aumentare la capacità produttiva.
Secondo i dati di BlueWhale Bio, si osserva una divisione cellulare precoce, rese cellulari più elevate e meno interventi di processo, e si segnala che i CDNP Synecta T1 sono utilizzati in un trial clinico CAR-T di 3 giorni.
Avantor (NYSE: AVTR) anunció una asociación estratégica con BlueWhale Bio el 15 de octubre de 2025 para acelerar la fabricación de CAR-T aumentando la producción de nanopartículas derivadas de células Synecta™ (CDNPs).
La colaboración combina las capacidades de bioprocesamiento y fabricación GMP de Avantor con la plataforma CDNP Synecta de BlueWhale Bio, con el objetivo de producir materiales CDNP de grado GMP para acortar el tiempo de expansión de CAR-T y aumentar la capacidad de manufactura.
Los datos de BlueWhale Bio citan una división celular más temprana, mayores rendimientos celulares y menos intervenciones del proceso, y señalan que los CDNP Synecta T1 se utilizan en un ensayo clínico CAR-T de 3 días.
Avantor (NYSE: AVTR)는 2025년 10월 15일 BlueWhale Bio와 전략적 제휴를 발표했고 Synecta™ 세포 유래 나노입자(CDNPs)의 생산 확대를 통해 CAR-T 제조를 가속화합니다.
이 협력은 Avantor의 바이오프로세싱 및 GMP 제조 역량과 BlueWhale Bio의 Synecta CDNP 플랫폼을 결합하여 GMP 등급 CDNP 재료를 생산하고 CAR-T 확장 시간을 단축하며 제조 능력을 증대하는 것을 목표로 합니다.
BlueWhale Bio 데이터는 앞선 세포 분열, 더 높은 세포 수율, 그리고 더 적은 프로세스 개입을 인용하며 Synecta T1 CDNP가 3일 CAR-T 임상시험에 사용된다고 밝힙니다.
Avantor (NYSE : AVTR) a annoncé le 15 octobre 2025 un partenariat stratégique avec BlueWhale Bio pour accélérer la fabrication de CAR-T en augmentant la production de nanoparticules dérivées de cellules Synecta™ (CDNPs).
Cette collaboration combine les capacités de bioprocédage et de fabrication GMP d'Avantor avec la plateforme CDNP Synecta de BlueWhale Bio, dans le but de produire des matériaux CDNP de qualité GMP afin de réduire le temps d'expansion du CAR-T et d'accroître la capacité de fabrication.
Les données de BlueWhale Bio évoquent une division cellulaire plus précoce, des rendements cellulaires plus élevés et moins d'interventions de processus, et indiquent que les CDNP Synecta T1 sont utilisés dans un essai clinique CAR-T de 3 jours.
Avantor (NYSE: AVTR) kündigte am 15. Oktober 2025 eine strategische Partnerschaft mit BlueWhale Bio an, um die CAR-T-Herstellung durch Skalierung der Produktion von Synecta™-zellulären Nanopartikeln (CDNPs) zu beschleunigen.
Die Zusammenarbeit kombiniert Avantors Bioprozessierungskompetenz und GMP-Fertigungskapazitäten mit BlueWhale Bios Synecta CDNP-Plattform, mit dem Ziel, CDNP-Materialien GMP-Qualität zu produzieren, um die CAR-T-Expansionszeit zu verkürzen und die Fertigungskapazität zu erhöhen.
BlueWhale Bio-Daten verweisen auf frühere Zellteilungen, höhere Zell-Ausbeuten und weniger Prozessinterventionen, und weisen darauf hin, dass Synecta T1 CDNPs in einer CAR-T-Klinischen Studie von 3 Tagen verwendet werden.
Avantor (NYSE: AVTR) أعلنت عن شراكة استراتيجية مع BlueWhale Bio في 15 أكتوبر 2025 لتسريع تصنيع CAR-T من خلال توسيع إنتاج جزيئات نانوية مشتقة من الخلايا Synecta™ (CDNPs).
تجمع الشراكة بين قدرات Avantor في المعالجة الحيوية والتصنيع GMP ومنصة Synecta CDNP الخاصة بـ BlueWhale Bio، بهدف إنتاج مواد CDNP عالية الجودة بحسب GMP لتقصير وقت توسيع CAR-T وزيادة الطاقة الإنتاجية.
تشير بيانات BlueWhale Bio إلى انقسام خلوي مبكر أعلى، ومخرجات خلوية أعلى، وتدخلات عمليات أقل، وتذكر أن CDNPs Synecta T1 تستخدم في تجربة سريرية CAR-T تستغرق 3 أيام.
Avantor (NYSE: AVTR) 宣布于2025年10月15日与 BlueWhale Bio 建立战略伙伴关系，以通过扩大 Synecta™ 细胞来源纳米颗粒（CDNPs）的生产来加速 CAR-T 制造。
此次合作将 Avantor 的生物加工与 GMP 制造能力与 BlueWhale Bio 的 Synecta CDNP 平台相结合，目标是生产 GMP 级 CDNP 材料，以缩短 CAR-T 的扩增时间并提升制造产能。
BlueWhale Bio 的数据提到早期的细胞分裂、较高的细胞产量以及较少的工艺干预，并指出 Synecta T1 CDNP 被用于一个 3 天的 CAR-T 临床试验。
- GMP-grade CDNP production partnership to support scale-up
- Synecta T1 CDNPs in a 3-day CAR-T clinical trial
- Preclinical/clinical data show earlier cell division and higher cell yields
- None.
Insights
Partnership pairs Avantor's GMP manufacturing scale with BlueWhale Bio's Synecta™ CDNPs to target faster, more consistent CAR-T production.
The collaboration merges Avantor manufacturing capabilities with BlueWhale Bio’s Synecta™ cell‑derived nanoparticle (CDNP) platform to produce GMP‑grade CDNP materials aimed at shortening CAR‑T expansion time and reducing process variability. The business mechanism is straightforward: supply‑chain and reagent scale‑up from a large CMO/provider to enable clinical and commercial use of a next‑generation activation/expansion reagent.
Key dependencies and risks center on clinical and manufacturing validation: the announced data are described as from preclinical and clinical programs showing earlier division and higher yields, and a clinical trial is using a 3‑day CAR‑T manufacturing process, but the release does not state regulatory approvals, full clinical outcomes, or validated large‑scale GMP runs. Operational risks include achieving consistent GMP CDNP quality at scale and integrating the reagent into diverse developers’ workflows without increasing regulatory or release complexity.
Watch for concrete near‑term milestones such as successful GMP lot release, submission of supporting manufacturing data, and any clinical readouts tied to the Synecta™ CDNP‑enabled processes; these items will clarify commercial adoption over the next 6–24 months. The announcement is a positive operational development for manufacturing capacity and reagent availability, contingent on demonstrated GMP scale‑up and clinical confirmation of the claimed process benefits.
The partnership combines Avantor's bioprocessing and custom ancillary-reagent manufacturing capabilities with BlueWhale Bio's Synecta™ cell-derived nanoparticle (CDNP) platform, which mimics natural T-cell stimulation. The collaboration aims to accelerate CDNP manufacturing scale-up to help CAR-T developers significantly reduce expansion time - potentially expanding patient access and manufacturing capacity across the growing cell therapy sector. Together, the teams will produce GMP-grade CDNP materials to support this next-generation manufacturing approach.
"Our partnership with BlueWhale Bio reflects Avantor's commitment to delivering highly relevant manufacturing solutions to customers and enabling next-generation therapies through innovation, reliability, and scale," said Emmanuel Ligner, President and Chief Executive Officer of Avantor. "CAR-T therapies have transformed cancer care, but manufacturing remains a major bottleneck characterized by high cost, variability, and lengthy release cycles. The Avantor–BlueWhale Bio collaboration addresses these challenges by integrating next-generation activation and expansion reagents into a GMP-ready, scalable platform."
Data from BlueWhale Bio's preclinical and clinical programs demonstrate earlier cell division, higher cell yields, and fewer process interventions, indicating potential to reduce CAR-T process time and reduce cell stress during manufacturing. Synecta™ T1 CDNPs are used in a clinical trial using 3-day CAR-T manufacturing.
"BlueWhale Bio was founded to address the toughest manufacturing challenges in cell therapy. Failure to meet target dose levels in immune cell therapies can have a critical downstream impact on patients," said Peter Keller, Chief Executive Officer of BlueWhale Bio. "By partnering with Avantor, we're combining our novel Synecta™ platform with industrial-strength execution to accelerate the journey from discovery to delivery."
About Avantor
Avantor® is a leading life science tools company and global provider of mission-critical products and services to the life sciences and advanced technology industries. We work side-by-side with customers at every step of the scientific journey to enable breakthroughs in medicine, healthcare, and technology. Our portfolio is used in virtually every stage of the most important research, development and production activities at more than 300,000 customer locations in 180 countries. For more information, visit avantorsciences.com and find us on LinkedIn, X (Twitter) and Facebook.
About BlueWhale Bio
BlueWhale Bio is dedicated to accelerating the growth and adoption of cell-based therapies by transforming the manufacturing process of immune cell therapy. The company is developing a portfolio of critical materials that bring the full benefits of higher-performing cell therapies to more patients faster and at lower costs. Its first product, Synecta™ T1, is used in a phase 1 clinical trial for a 3-day manufacturing process of an armored CAR-T. BlueWhale's innovations are based on cutting-edge discoveries in cell activation led by Dr. Carl June and Dr. Jim Riley at the University of
Avantor Media Contact
Eric Van Zanten
Head of External Communications
Avantor
610-529-6219
Eric.Vanzanten@avantorsciences.com
Avantor Investor Relations Contact
Allison Hosak
Senior Vice President, Global Communications
Avantor
908-329-7281
Allison.Hosak@avantorsciences.com
BlueWhale Bio Media Contact
Cammy Duong
cduong@bluewhale.bio
View original content:https://www.prnewswire.com/news-releases/avantor-and-bluewhale-bio-partner-to-accelerate-car-t-manufacturing-with-breakthrough-cell-activation-and-expansion-technology-302583953.html
SOURCE Avantor and Financial News
FAQ
What did Avantor (AVTR) announce on October 15, 2025 about CAR-T manufacturing?
How could the Avantor–BlueWhale Bio partnership affect CAR-T production timelines for AVTR investors?
Does the Avantor (AVTR) release disclose financial terms or timelines for the CDNP scale-up?
What evidence supports the Synecta platform mentioned in Avantor's AVTR partnership?
Will Avantor (AVTR) manufacture clinical-grade Synecta materials?
